Janux Therapeutics, Inc.

NASDAQ (USD): Janux Therapeutics, Inc. (JANX)

Last Price

43.99

Today's Change

+1.23 (2.87%)

Day's Change

42.81 - 44.96

Trading Volume

410,223

Overview

Market Cap

2 Billion

Shares Outstanding

51 Million

Avg Volume

804,039

Avg Price (50 Days)

44.11

Avg Price (200 Days)

27.77

PE Ratio

-36.66

EPS

-1.20

Earnings Announcement

06-Aug-2024

Previous Close

42.76

Open

43.48

Day's Range

42.81 - 44.965

Year Range

5.65 - 65.6

Trading Volume

410,223

Price Change Highlight

1 Day Change

2.88%

5 Day Change

1.76%

1 Month Change

10.53%

3 Month Change

-7.17%

6 Month Change

371.49%

Ytd Change

299.18%

1 Year Change

233.51%

3 Year Change

54.84%

5 Year Change

74.91%

10 Year Change

74.91%

Max Change

74.91%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment